Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNYYYYYYY (where YYYYYYY represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Influence of Localization of Primary Tumor on Effectiveness of 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) in Patients with Metastatic Pancreatic Adenocarcinoma: A Retrospective Study. V. LORGIS, B. CHAUFFERT, J. GENTIL, F. GHIRINGHELLI (Dijon; Amiens, France) ........................................................................................................................ .................

Feasibility Study of Zoledronic Acid plus Cisplatin-Docetaxel as First-line Treatment for Advanced Non-small Cell Lung Cancer with Bone Metastases. K. YOH, K. KUBOTA, H. OHMATSU, K. GOTO, S. NIHO, Y. OHE (Chiba, Japan) ........................................................................................................


Gemcitabine-induced Pulmonary Toxicity. D.-C. CHI, F. BROGAN, I. TURENNE, S. ZELONIS, L. SCHWARTZ, M.W. SAIF (Boston, MA, USA)...................................................................................


Long-term Results of a Phase II Study of S-1 plus Irinotecan in Metastatic Colorectal Cancer. S. IWASA, Y. YAMADA, K. KATO, A. GOTO, Y. HONMA, T. HAMAGUCHI, Y. SHIMADA (Tokyo; Yokohama, Japan) ............................................................

Use of Pretreatment Metabolic Tumor Volumes on PET-CT to Predict the Survival of Patients with Squamous Cell Carcinoma of Esophagus Treated by Curative Surgery. W.-Y. SHUM, H.-J. DING, J.-A. LIANG, K.-Y. YEN, S.-W. CHEN, C.-H. KAO (Taichung; Kaohsiung, Taiwan, ROC) ........................................

Errata ….........................................................................................................................
Systemic Inflammatory Response Predicts Perioperative Central Venous Catheter-related Bloodstream Infection in Patients Undergoing Colorectal Cancer Surgery with Administration of Parenteral Nutrition. M. ISHIZUKA, H. NAGATA, K. TAKAGI, Y. IWASAKI, K. KUBOTA (Tochigi, Japan) ................................................................. 4045

A Case of Synchronous Metastasis of Breast Cancer to Stomach and Colon. H. TAKEUCHI, S. HIROSHIGE, Y. YOSHIKAWA, T. KUSUMOTO, Y. MUTO (Beppu, Japan) ............................................................... 4051

Carcinoma of the Axillary Tail of Spence: A Case Series. F. AMPIL, G. CALDITO, B. HENDERSOEN, B. LI, R.H. KIM, G. BURTON, Q. CHU (Shreveport, LA, USA) ........................................................ 4057

Histological Grade Predicts for Recurrence in Patients with Uterine Endometrioid Carcinoma without Myometrial Involvement. M.A. ZAKI, J.R. ROBBINS, S. FATTEH, M.G. MAHAN, R.K. HANNA, M.A. ELSHAIKH (Detroit, MI, USA) ................................................................. 4061

High Levels of HMGB1 in Plasma May Be due to Ex Vivo Cell Necrosis. P. NOWAK, J. NYSTROM, M. TROSEID (Stockholm, Sweden; Oslo, Norway) ................................................................. 4067


Carotid Intima-media Thickness and Laboratory Parameters of Atherosclerosis Risk in Patients with Breast Cancer. B. MELICHAR, H. KALÁBOVÁ, L. UNGERMANN, L. KRČMOVÁ, R. HYŠPLER, M. KAŠPAROVA, M. PECKA, V. ŠRÁMEK, H. PROCHÁZKOVA-ŠTUDENTOVÁ, A. SVOBODNÍK, L. PECEN, D. SOLICHOVÁ (Olomouc; Hradec Králové; Brno, Czech Republic) .................. 4077


Colon Neoplastic Cells Do Not Originate from Bone Marrow-derived Cells after Sex-mismatched Bone Marrow Transplantation. G. SAKAI, T. YAJIMA, H. TAKAISHI, T. MORI, H. HIGUCHI, S. NAKAMURA, S. FUNAKOSHI, M. ADACHI, M. IZUMIYA, H. AKAGI, Y. HAMAMOTO, T. KANAI, M. MUKAI, S. OKAMOTO, T. HIBI (Tokyo, Japan) ................................................................. 4097

Rapid Relapse after Resection of a Sunitinib-resistant Gastrointestinal Stromal Tumor Harboring a Secondary Mutation in Exon 13 of the c-KIT Gene. H. KIKUCHI, S. MIYAZAKI, T. SETOGUCHI, Y. HIRAMATSU, M. OHTA, K. KAMAYA, T. SAKAGUCHI, H. KONNO (Hamamatsu, Japan) ................................................................. 4105


Lenalidomide-associated Hepatotoxicity – A Case Report and Literature Review. B. NOJKOV, C. SIGNORI, A. KONDA, R.J. FONTANA (Royal Oak; Ann Arbor, MI; Hershey, PA, USA) ................................................................. 4117

Hepatic Arterial Thrombosis: A Critical Complication During Combination Therapy of Arterial Chemoinfusion and Sorafenib. H. NISHIOFUKU, T. TANAKA, H. ANAI, S. SUEYOSHI, S. MAEDA, T. MASADA, K. KICHIKAWA (Nara, Japan) ................................................................. 4121

Contents continued on the preceding page
Expression of p53 and Ki-67 as Prognostic Factors for Survival of Men with Colorectal Cancer. F. LUMACHI, R. ORLANDO, F. MARINO, G.B. CHIARA, S.M.M. BASSO (Padova; Pordenone, Italy) 3965

Health-related Quality of Life During Sequential Chemotherapy with Carboplatin Followed by Weekly Paclitaxel in Advanced Ovarian Cancer: A Multicenter Phase II Study of the North Eastern German Society of Gynecological Oncology. R. RICHTER, G. OKSAY-ÖZCELIK, R. CHEKEROV, A. PILGER, H.-J. HINDENBURG, H. SOMMER, O. CAMARA, E. KEIL, J. EINENKEL, J. SEHOULI (Berlin; Munich; Jena; Leipzig, Germany) 3969

Association of Syndecan-1 with Angiogenesis-related Markers, Extracellular Matrix Components, and Clinicopathological Features in Colorectal Carcinoma. A. MITSELOU, U. SKOUFI, K.E. TSIMOGIANNIS, E. BRIASOULIS, T. VOUGIOUKLAKIS, D. ARVANITIS, E. IOACHIM (Ioannina; Larisa, Greece) 3977

High Nuclear Protein Kinase CβII Expression Is a Marker of Disease Recurrence in Oral Squamous Cell Carcinoma. P.-Y. CHU, N.C.-H. HSU, S.-H. LIN, M.-F. HOU, K.-T. YEH (Chiai; Kaohsiung; Changhua; Miaoli; Taichung, Taiwan, ROC) 3987

The Expression of β-Microseminoprotein but Not CRISP3 Is Reduced in Ovarian Cancer and Correlates to Survival. R. HENRIKSEN, E. LUNDWALL, L. UDBY, P. FERNLUND (Malmö, Sweden; Copenhagen, Denmark) 3993

* Review: A Review of Dose-dense Temozolomide Alone and in Combination with Bevacizumab in Patients with First Relapse of Glioblastoma. F. JOHANSSON, S. EKMAN, E. BLOMQUIST, R. HENRIKSSON, S. BERGSTRÖM, M. BERGQVIST (Uppsala; Umeå; Stockholm; Göteborg, Sweden) 4001

* Review: The Role of Cetuximab in the Treatment of Metastatic Colorectal Cancer. L. HOLUBEC, V. LISKA, V.M. MATEJKA, O. FIALA, J. DRESLEROVA, P. MRAZKOVA, V. TRESKA, J. FINEK (Prague, Czech Republic) 4007

Hyperfractionated Radiotherapy with Concurrent Docetaxel for Advanced Head and Neck Cancer: A Phase II Study. K. KARASAWA, F. MATSUMOTO, S. ITO, S. OBA, T. FURUYA, H. HIROWATARI, H. IZAWA, K. ITO, K. SASAI (Chiba; Tokyo, Japan) 4013

A Phase I Study of Concurrent Chemoradiotherapy and Cetuximab for Locally Advanced Esophageal Cancer. C. HOLLÄNDER, L. BAEKSGAARD, M. SORENSEN, P. ALBERTSSON, L. DAMSTRUP, U. LASSEN (Copenhagen, Denmark) 4019

Role of Conservative (Palliative) Care-only in the Management of Advanced Malignant Pleural Mesothelioma. A. LEVY, A. ASSOULINE, S. RIVERA, C. CHARGARI, P. TAI (Villejuif; Boulogne-Billancourt; Paris, France; Regina, Saskatchewan, Canada) 4025


Feasibility of Concurrent Chemoradiotherapy with S-1 Administered on Alternate Days for Elderly Patients with Head and Neck Cancer. Y. KOGASHIWA, H. NAGAFUJI, N. KOHNO (Tokyo, Japan) 4035


Contents continued on the preceding page

Chemotherapy Dose-intensity and Survival for Childhood Medulloblastoma. R.L. SMITH, X. SHI, E.J. ESTLIN (Manchester, UK) .................................................

Gene Expression Profiling of Adult t(4;11)(q21;q23)-associated Acute Lymphoblastic Leukemia Reveals a Different Signature from Pediatric Cases. E. DE BRAKELEER, N. DOUET-GUILBERT, M.-J. LE BRIS, A. BASINKO, F. MOREL, M. DE BRAKELEER (Brest, France) ....................................................


Association of Matrix Metalloproteinase-1 Polymorphisms with Risk of COPD and Lung Cancer and Survival in Lung Cancer. L. ENEWOLD, L.E. MECHANIC, E.D. BOWMAN, E.A. PLATZ, A.J. ALBERG (Baltimore; Rockville; Bethesda, MD; Charleston, SC, USA) .............................................................

SERPINA1 and ELA2 Polymorphisms Are Not Associated with COPD or Lung Cancer. L. ENEWOLD, L.E. MECHANIC, E.D. BOWMAN, E.A. PLATZ, A.J. ALBERG (Baltimore; Rockville; Bethesda, MD; Charleston, SC, USA) .............................................................

Detection and Quantification of Human Papillomavirus in Benign and Malignant Parotid Lesions. G. DESCAMPS, A. DURAY, A. RODRIGUEZ, G. CHANTRAIN, C.E. DEPUYDT, P. DELVENNE, S. SAUSSEZ (Mons; Antwerp; Liège; Brussels, Belgium) ....................................................................... 

Compliance, Analgesic Use and Side-effect Protection within a German Cohort of the TEAM Trial. M. BOSSART, M. BECKER, P. HADJJ, D.G. KIEBACK, A. HASENBURG (Freiburg; Marburg; Riesa, Germany) ..............................................................

A Randomized Controlled Non-inferiority Study Comparing the Antiemetic Effect between Intravenous Granisetron and Oral Azasetron Based on Estimated 5-HT3 Receptor Occupancy. J. ENDO, H. IIHARA, M. YAMADA, K. YANASE, F. KAMIYA, F. ITO, N. FUNAGUCHI, Y. OHNO, S. MINATOGUCHI, Y. ITOH (Gifu, Japan) ..............................................................................................................

Combining Paclitaxel and Lapatinib as Second-line Treatment for Patients with Metastatic Transitional Cell Carcinoma: A Case Series. S. CULINE, Z. SELLAM, L. BOUAITA, E. ASSAF, C. DELBALDO, M. VERLINDE-CARVALHO, D. POUESSEL (Crêteil, France) ............................................................................

* Review: Prediction of Recurrence after Complete Resection in Patients with NSCLC. H. URAMOTO, F. TANAKA (Kitakyushu, Japan) ..............................................................


Contents continued on the preceding page

Knockdown of Receptor-Interacting Serine/Threonine Protein Kinase-2 (RIPK2) Affects EMT-associated Gene Expression in Human Hepatoma Cells. S. WU, T. KANDA, S. NAKAMOTO, F. IMAZEKI, O. YOKOSUKA (Chiba, Japan) .......................................................... 3775

Prognostic Value of Aquired Resistance-related Molecules in Japanese Patients with NSCLC Treated with an EGFR-TKI. H. URAMOTO, T. YAMADA, S. YANO, N. KONDO, S. HASEGAWA, F. TANAKA (Kitakyushu; Kanazawa; Hyogo, Japan) ............................................. 3785

The Effects of N-acetylcysteine on Ifosfamide Efficacy in a Mouse Xenograft Model. L. HANLY, R. FIGUEREDO, M.J. RIEDER, J. KOROPATNICK, G. KOREN (London; Toronto, ON, Canada) ................. 3791


Significant Anti-invasive Activities of α-Mangostin from the Mangosteen Pericarp on two Human Skin Cancer Cell Lines. J.J. WANG, B.J.S. SANDERSON, W. ZHANG (Bedford Park, Adelaide, Australia) .... 3805

Serum Platelet-derived Growth Factor and Fibroblast Growth Factor in Patients with Benign and Malignant Ovarian Tumors. C.V. MADSEN, K.D. STEFFENSEN, D.A. OLSEN, M. WALDSTRØM, C.H. SØGAARD, I. BRANDSLUND, A. JAKOBSEN (Vejle; Odense; Skejby, Denmark) .................................................... 3817

Nuclear Expression of Yes-associated Protein 1 Correlates with Poor Prognosis in Intestinal Type Gastric Cancer. M. SONG, J.-H. CHEONG, H. KIM, S.H. NOH, H. KIM (Seoul, Republic of Korea) ......................... 3827


NAC1, a BTB/POZ Protein Overexpressed in Uterine Sarcomas. M.T. RAHMAN, K. NAKAYAMA, M. ISHIKAWA, M. RAHMAN, H. KATAGIRI, A. KATAGIRI, T. ISHIBASHI, K. IIDA, T. YAMADA, K. MIYAZAKI (Shimane; Osaka, Japan) .................................................... 3841


Clinical Studies

Cancer Immunotherapy by Intratumoral Injection of α-gal Glycolipids. G.F. WHALEN, M. SULLIVAN, B. PIPERDI, W. WASSEFF, U. GALILI (Worcester, MA, USA) ................................................................. 3861


Contents continued on the preceding page
Administration of Salubrinal Enhances Radiation-induced Cell Death of SW1353 Chondrosarcoma Cells. M. KOIZUMI, N.G. TANJIUNG, A. CHEN, J.R. DYNLACHT, J. GARRETT, Y. YOSHIOKA, K. OGAWA, T. TESHIMA, H. YOKOTA (Osaka, Japan; Indianapolis, IN, USA) .......................................................... 3667


Revisiting Epithelial-to-mesenchymal Transition through Adenoid Cystic Carcinoma. A. SIU, C. LEE, E. PHAM, D.M. RAMOS (San Francisco, CA, USA) ............................................................ 3683

A New Chalcone Derivative (E)-3-(4-Methoxyphenyl)-2-methyl-1- (3,4,5-trimethoxyphenyl)prop-2-en-1-one Suppresses Prostate Cancer Involving p53-mediated Cell Cycle Arrests and Apoptosis. Y. ZHANG, B. SRINIVASAN, C. XING, J. LÜ (Austin; Minneapolis, MN; Amarillo, TX, USA) ........................................ 3689

Site- and Grade-specific Diversity of LINE1 Methylation Pattern in Gastroenteropancreatic Neuroendocrine Tumours. I. STRICKER, D. TIZVIRAS, S. NAMBIAR, J. WULF, S.-T. LIFTERS, M. VOGT, B. VERDOODT, A. TANNAPFEL, A. MIRMOMHADSADEGH (Bochum, Germany) ........................................................................................................ 3699


PAR-1 Polymorphisms and Risk of Helicobacter pylori-related Gastric Cancer in a Chinese Population. N. CASTAÑO-RODRÍGUEZ, N.O. KAAKOUSH, K.-L. GOH, K.M. FOCK, Y.T. CHIONH, P. SUTTON, H.M. MITCHELL (Sydney; Melbourne, Australia; Singapore; Singapore; Kuala Lumpur, Malaysia) ....... 3715

An Easy Method to Quantify Plasma Cells/Plasma Cell Precursors in Normal Colonic Mucosa, Collagenous Colitis and Crohn’s Colitis. C.A. RUBIO (Stockholm, Sweden) ........................................................................................................ 3723

* Review: MicroRNAs in Renal Cell Carcinoma: Implications for Pathogenesis, Diagnosis, Prognosis and Therapy. B.M. AL-ALI, A.L. RESS, A. GERGER, M. PICHLER (Graz, Austria) ........................................................................................................ 3727


Gene Therapy Using Adenovirus Against Malignant Mesothelioma. A. GOTOH, T. KANNO, H. NAGAYA, T. NAKANO, C. TABATA, K. FUKUOKA, M. TAGAWA, T. NISHIZAKI (Nishinomiya; Chiba, Japan) ........... 3743

Pharmacokinetics of Intravenous Nitrosylcobalamin, an Antitumor Agent, in Healthy Beagle Dogs: A Pilot Study. A.M. SYSEL, W.I. HORNE, J.M. STEINER, J.S. SUCHODOLSKI, J.A. BAUER (Akron; Rootstown, OH; College Station, TX, USA) ............................................................. 3749

Significance of ELF3 mRNA Expression for Detection of Lymph Node Metastases of Colorectal Cancer. C. NAKARAI, K. OSAWA, N. MATSUBARA, H. IKEUCHI, T. YAMANO, S. OKAMURA, S. KAMOSHIDA, A. TSUTOU, J. TAKAHASHI, K. EJIRI, S. HIROTA, N. TOMITA, Y. KIDO (Kobe; Nishinomiya; Amagasaki; Himeji, Japan) ........................................................................................................ 3753

Extracellular ATP Induces Cytoplasmic and Nuclear Ca²⁺ Transients via P2Y2 Receptor in Human Biliary Epithelial Cancer Cells (Mz-Cha-1). C. ELSING, T. GEORGIEV, C.A. HÜBNER, R. BOGER, W. STREMMEl, T. SCHLENKER (Dorstten; Heidelberg; Jena, Germany) ........................................................................................................ 3759

Contents continued on the preceding page.